Liver International

• Analysis of the Efficacy of Treatment With Peginterferon Alpha-2a and Ribavirin in Patients Coinfected With Hepatitis B Virus And Hepatitis C Virus Investigators examined the virologic features of patients coinfected with HBV and HCV and the efficacy of combination therapy with peginterferon alpha-2a and ribavirin in these patients.
  Liver International, November 2009
• Pulmonary Dysfunction and Hepatopulmonary Syndrome in Cirrhosis and Portal Hypertension Investigators sought to determine the relationship between liver dysfunction and the prevalence of hepatopulmonary syndrome.
  Liver International, October 2009
• Treatment of Hepatitis C Virus Carriers With Persistently Normal Alanine Aminotransferase Levels With Peginterferon Alpha-2a and Ribavirin: A Multicentric Study This study assessed, in clinical practice, the efficacy and safety of combined antiviral treatment in hepatitis C virus (HCV) carriers with normal alanine aminotransferase (ALT) levels.
  Liver International, October 2009
• Current Management of Hepatitis B Virus Infection Before and After Liver Transplantation This article focuses on data in the management of HBV transplant patients to assess the optimal pretransplant setting regimen, post-transplant prophylaxis, and therapy of HBV recurrent infection.
  Liver International, October 2009
• Early Prediction of Sustained Virological Response at Day 3 of Treatment With Albinterferon-alpha-2b in Patients With Genotype 2/3 Chronic Hepatitis C Investigators evaluated the association of initial viral kinetics during albIFN therapy with baseline factors and sustained virologic response prediction.
  Liver International, October 2009
• Protein-Calorie Malnutrition as a Prognostic Indicator of Mortality Among Patients Hospitalized With Cirrhosis and Portal Hypertension A nationwide analysis of the prevalence of protein-calorie malnutrition in patients with cirrhosis and portal hypertension and its impact on mortality and healthcare costs are discussed.
  Liver International, October 2009
• Serum Adipokine Levels Predictive of Liver Injury in Non-alcoholic Fatty Liver Disease Investigators sought to determine whether serum levels of adipokines, including the ratio of serum adiponectin to leptin levels, could predict the severity of liver injury in patients with NAFLD.
  Liver International, October 2009
• Hypoxia-Inducible Factor-Dependent Production of Profibrotic Mediators by Hypoxic Hepatocytes This study evaluated whether hypoxia-inducible factor-1alpha (HIF-1alpha) is activated in hypoxic hepatocytes and regulates the production of profibrotic mediators by these cells.
  Liver International, August 2009
• Endothelin Inhibits Cholangiocarcinoma Growth by a Decrease in the Vascular Endothelial Growth Factor Expression This study assessed the effects of ET-1 on cholangiocarcinoma growth in Mz-ChA-1 cells and nude mice and whether ET-1 regulation of such growth affects changes in VEGF and VEGF receptor expression
  Liver International, August 2009
• Liver Cancer Stem Cells: Implications for a New Therapeutic Target This study reviews the origin of liver stem cells and its relation to HCC development, summarizes the current cancer stem cell markers in HCC, and discusses their relevance to the treatment of HCC.
  Liver International, August 2009
• Impaired Liver Regeneration With Humoral and Genetic Disturbances in Urinary Trypsin Inhibitor-Deficient Mice This study attempted to determine the role of urinary trypsin inhibitor (UTI) in liver regeneration with the use of genetically UTI-deficient mice.
  Liver International, August 2009
• Deficiency in Calcineurin Activity in Liver Transplantation Candidates With Alcoholic Cirrhosis or Hepatocellular Carcinoma This study evaluated baseline calcineurin phosphatase activity in liver transplant candidates with alcoholic cirrhosis or HCC and investigated factors that might modify it.
  Liver International, July 2009
• Eradication of Hepatitis C Virus by Interferon Improves Whole-Body Insulin Resistance and Hyperinsulinaemia in Patients With Chronic Hepatitis C Does eradication of hepatitis C virus by interferon therapy influence systemic glucose metabolism? This study takes a look.
  Liver International, July 2009
• Features and Consequences of Untreated Type 1 Autoimmune Hepatitis This study attempted to determine the existence, characteristics, and outcome of a mild form of autoimmune hepatitis.
  Liver International, July 2009
• Significance of Antibodies to Soluble Liver Antigen/Liver Pancreas: a Large French Study This large study assessed whether antibodies to soluble liver antigen/liver pancreas are of diagnostic value for type 1 autoimmune hepatitis and other liver diseases.
  Liver International, July 2009
• Mycoplasma Antigens as a Possible Trigger for the Induction of Antimitochondrial Antibodies in Primary Biliary Cirrhosis Does molecular mimicry between surface molecules of mycoplasma and epitopes of the autoantigen play an etiopathologic role in primary biliary cirrhosis?
  Liver International, July 2009
• Endogenous Alpha-Calcitonin Gene-Related Peptide Mitigates Liver Fibrosis in Chronic Hepatitis Induced by Repeated Administration of Concanavalin A This study evaluated whether alpha-calcitonin gene-related peptide mitigates liver fibrosis in chronic hepatitis induced by repeated administration of concanavalin A.
  Liver International, May 2009
• Beta-Blockers Protect Against Spontaneous Bacterial Peritonitis in Cirrhotic Patients: A Meta-Analysis This meta-analysis assessed the possible role of beta-blockers in preventing spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites.
  Liver International, May 2009
• Predictive Factors of Advanced Recurrence After Curative Resection of Small Hepatocellular Carcinoma This study analyzed the clinical and histologic characteristics of small HCC and evaluated the predictive factors of advanced tumor recurrence.
  Liver International, May 2009
• Gene Expression Profile of Huh-7 Cells Expressing Hepatitis C Virus Genotype 1b Or 3a Core Proteins This study attempted to identify HCV genotype-specific virus-host interactions that could account for the diseases variable expression and potentially lead to clinically significant consequences.
  Liver International, May 2009